Factors influencing the concordance of histological subtype diagnosis from biopsy and resected specimens of lung adenocarcinoma

Lung Cancer

Volumn 94, Issue , 2016, Pages 1-6

  Matsuzawa, Reiko ^a,b   Kirita, Keisuke ^b   Kuwata, Takeshi ^a   Umemura, Shigeki ^b   Matsumoto, Shingo ^b   Fujii, Satoshi ^a   Yoh, Kiyotaka ^b   Kojima, Motohiro ^a   Niho, Seiji ^b   Ohmatsu, Hironobu ^b   Ochiai, Atsushi ^a   Tsuboi, Masahiro ^b   Goto, Koichi ^b   Ishii, Genichiro ^a  

^a NATIONAL CANCER CENTER   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Biopsy specimen; IASLC ATS ERS classification; Predominant subtype; Resected specimen

Indexed keywords

ACINAR ADENOCARCINOMA; ADULT; AGED; ARTICLE; BIOPSY; BRONCHUS BIOPSY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER SIZE; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; FEMALE; HISTOLOGY; HUMAN; LEPIDIC ADENOCARCINOMA; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MICROPAPILLARY ADENOCARCINOMA; PAPILLARY ADENOCARCINOMA; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SOLID ADENOCARCINOMA; VERY ELDERLY; ADENOCARCINOMA; CANCER STAGING; FACTOR ANALYSIS; LUNG NEOPLASMS; MIDDLE AGED; POSTOPERATIVE PERIOD; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; TUMOR BURDEN;

EID: 84960414518     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.01.009     Document Type: Article

References (23)

1. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K.R., Yatabe Y., Beer D.G., Powell C.A., Riely G.J., Van Schil P.E., Garg K., Austin J.H., Asamura H., Rusch V.W., Hirsch F.R., Scagliotti G., Mitsudomi T., Huber R.M., Ishikawa Y., Jett J., Sanchez-Cespedes M., Sculier J.P., Takahashi T., Tsuboi M., Vansteenkiste J., Wistuba I., Yang P.C., Aberle D., Brambilla C., Flieder D., Franklin W., Gazdar A., Gould M., Hasleton P., Henderson D., Johnson B., Johnson D., Kerr K., Kuriyama K., Lee J.S., Miller V.A., Petersen I., Roggli V., Rosell R., Saijo N., Thunnissen E., Tsao M., Yankelewitz D. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J. Thorac. Oncol. 2011, 6:244-285.
2. Hung J.J., Yeh Y.C., Jeng W.J., Wu K.J., Huang B.S., Wu Y.C., Chou T.Y., Hsu W.H. Predictive value of the international association for the study of lung cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival. J. Clin. Oncol. 2014, 32:2357-2364.
3. Campos-Parra A.D., Aviles A., Contreras-Reyes S., Rojas-Marin C.E., Sanchez-Reyes R., Borbolla-Escoboza R.J., Arrieta O. Relevance of the novel IASLC/ATS/ERS classification of lung adenocarcinoma in advanced disease. Eur. Respir. J. 2014, 43:1439-1447.
4. Hung J.J., Jeng W.J., Chou T.Y., Hsu W.H., Wu K.J., Huang B.S., Wu Y.C. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma. Ann. Surg. 2013, 258:1079-1086.
5. Yoshizawa A., Motoi N., Riely G.J., Sima C.S., Gerald W.L., Kris M.G., Park B.J., Rusch V.W., Travis W.D. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod. Pathol. 2011, 24:653-664.
6. Warth A., Muley T., Meister M., Stenzinger A., Thomas M., Schirmacher P., Schnabel P.A., Budczies J., Hoffmann H., Weichert W. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J. Clin. Oncol. 2012, 30:1438-1446.
7. Russell P.A., Wainer Z., Wright G.M., Daniels M., Conron M., Williams R.A. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J. Thorac. Oncol. 2011, 6:1496-1504.
8. Yoshizawa A., Sumiyoshi S., Sonobe M., Kobayashi M., Fujimoto M., Kawakami F., Tsuruyama T., Travis W.D., Date H., Haga H. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J. Thorac. Oncol. 2013, 8:52-61.
9. Tsao M.S., Marguet S., Le Teuff G., Lantuejoul S., Shepherd F.A., Seymour L., Kratzke R., Graziano S.L., Popper H.H., Rosell R., Douillard J.Y., Le-Chevalier T., Pignon J.P., Soria J.C., Brambilla E.M. Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection. J. Clin. Oncol. 2015.
10. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart 2015, Internatilnal Agency for Reserch on Cancer, Lyon. fourth ed. W.D. Travis, E. Brambilla, A.P. Burke, A. Marx, A.G. Nicholson (Eds.).
11. Warth A., Cortis J., Fink L., Fisseler-Eckhoff A., Geddert H., Hager T., Junker K., Kayser G., Kitz J., Langer F., Morresi-Hauf A., Ott G., Petersen I., Stenzinger A., Soltermann A., Ting S., Tischler V., Vollmer E., Schnabel P.A., Weichert W. Training increases concordance in classifying pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS classification. Virchows Arch. 2012, 461:185-193.
12. Yoshida T., Ishii G., Goto K., Yoh K., Niho S., Umemura S., Matsumoto S., Ohmatsu H., Nagai K., Ohe Y., Ochiai A. Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma. J. Cancer Res. Clin. Oncol. 2013, 139:1691-1700.
13. Hu H., Pan Y., Li Y., Wang L., Wang R., Zhang Y., Li H., Ye T., Zhang Y., Luo X., Shao L., Sun Z., Cai D., Xu J., Lu Q., Deng Y., Shen L., Ji H., Sun Y., Chen H. Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma. Oncol. Targets Ther. 2014, 7:1423-1437.
14. Pan Y., Zhang Y., Li Y., Hu H., Wang L., Li H., Wang R., Ye T., Luo X., Zhang Y., Li B., Cai D., Shen L., Sun Y., Chen H.A.L.K. ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer 2014, 84:121-126.
15. Zhang Y., Wang R., Cai D., Li Y., Pan Y., Hu H., Wang L., Li H., Ye T., Luo X., Zhang Y., Li B., Shen L., Sun Y., Chen H. A comprehensive investigation of molecular features and prognosis of lung adenocarcinoma with micropapillary component. J. Thorac. Oncol. 2014, 9:1772-1778.
16. Yanagawa N., Shiono S., Abiko M., Ogata S.Y., Sato T., Tamura G. The correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma. Ann. Thorac. Surg. 2014, 98:453-458.
17. Tsuta K., Kawago M., Inoue E., Yoshida A., Takahashi F., Sakurai H., Watanabe S., Takeuchi M., Furuta K., Asamura H., Tsuda H. The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung Cancer 2013, 81:371-376.
18. Inamura K., Takeuchi K., Togashi Y., Hatano S., Ninomiya H., Motoi N., Mun M.Y., Sakao Y., Okumura S., Nakagawa K., Soda M., Choi Y.L., Mano H., Ishikawa Y. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod. Pathol. 2009, 22:508-515.
19. Shim H.S., Lee da H., Park E.J., Kim S.H. Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification. Arch. Pathol. Lab. Med. 2011, 135:1329-1334.
20. Yoshida A., Tsuta K., Nitta H., Hatanaka Y., Asamura H., Sekine I., Grogan T.M., Fukayama M., Shibata T., Furuta K., Kohno T., Tsuda H. Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas. J. Thorac. Oncol. 2011, 6:1677-1686.
21. Takeuchi K., Choi Y.L., Togashi Y., Soda M., Hatano S., Inamura K., Takada S., Ueno T., Yamashita Y., Satoh Y., Okumura S., Nakagawa K., Ishikawa Y., Mano H. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin. Cancer Res. 2009, 15:3143-3149.
22. Thunnissen E., Beasley M.B., Borczuk A.C., Brambilla E., Chirieac L.R., Dacic S., Flieder D., Gazdar A., Geisinger K., Hasleton P., Ishikawa Y., Kerr K.M., Lantejoul S., Matsuno Y., Minami Y., Moreira A.L., Motoi N., Nicholson A.G., Noguchi M., Nonaka D., Pelosi G., Petersen I., Rekhtman N., Roggli V., Travis W.D., Tsao M.S., Wistuba I., Xu H., Yatabe Y., Zakowski M., Witte B., Kuik D.J. Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma: An international interobserver study. Mod. Pathol. 2012, 25:1574-1583.
23. Warth A., Stenzinger A., von Brunneck A.C., Goeppert B., Cortis J., Petersen I., Hoffmann H., Schnabel P.A., Weichert W. Interobserver variability in the application of the novel IASLC/ATS/ERS classification for pulmonary adenocarcinomas. Eur. Respir. J. 2012, 40:1221-1227.